Ambee Pharmaceuticals PLC announcements
253 Dhaka Stock Exchange announcements for Ambee Pharmaceuticals PLC (AMBEEPHA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (20).
- Resumption after Record date
Trading of the shares of the company will resume on 26.11.2023.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 23.11.2023.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 21.11.2023 to 22.11.2023 and trading of the shares will remain suspended on record date i.e., 23.11.2023.
- The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the
The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.dsebd.org/assets/pdf/Qualified\%20Opinion\%20of\%20Ambee\%20Pharmaceuticals\%20PLC\%20for\%20the\%20year\%20ended\%20on\%2030\%20June\%202023.pdf
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.60 for July-September 2023 as against Tk. 0.25 for July-September 2022; NOCFPS was Tk. (0.49) for July-September 2023 as against Tk. 4.34 for July-September 2022. NAV per share was Tk. 10.33 as on September 30, 2023 and Tk. 9.73 as on June 30, 2023.
- Change of AGM Time
Refer to their earlier news disseminated by DSE on 05.11.2023 regarding dividend declaration and increase of paid up capital, the company has further informed that the time of AGM will be 4:00 PM instead of 11:00 AM. The date and venue of the AGM will remain unchanged.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (05.11.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration and increase of paid up capital
The Board of Directors has recommended 15% Cash Dividend for the year ended June 30, 2023. Date of AGM: 14.12.2023, Time: 11:00 AM, Venue: Digital Platform. Record date: 23.11.2023. The Company has also reported EPS of Tk. 3.79, NAV per share of Tk. 9.73 and NOCFPS of Tk. (14.68) for the year ended June 30, 2023 as against Tk. 3.36, Tk. 21.96 and Tk. (30.49) respectively for the year ended June 30, 2022. The Board also recommended paid up capital to be increased from TK. 2.40 Crore to TK. 30.00 Crore.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 02, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Query Response
In response to a DSE query dated September 27, 2023, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Name Change of the Company
Dhaka Stock Exchange Limited (DSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Ambee Pharmaceuticals PLC' instead of 'Ambee Pharmaceuticals Ltd.' with effect from August 09, 2023. Other things (except name) will remain unchanged.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.70 for January-March 2023 as against Tk. 0.40 for January-March 2022; EPS was Tk. 1.34 for July 2022-March 2023 as against Tk. 0.74 for July 2021-March 2022. NOCFPS was Tk. 0.38 for July 2022-March 2023 as against Tk. 2.18 for July 2021-March 2022. NAV per share was Tk. 19.02 as on March 31, 2023 and Tk. 21.96 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 16, 2023 at 2:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Appointment of Company Secretary
The company has informed that the Board of Directors has approved Mr. Mohammad Amir Hossain as Company Secretary of the company with effect from April 01, 2023.
- Appointment of Chief Financial Officer
The company has informed that the Board of Directors has approved Mr. A.K.M. Khairul Aziz as Chief Financial Officer of the company with effect from March 23, 2023.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.35 for October-December, 2022 as against Tk. 0.24 for October-December, 2021; EPS was Tk. 0.60 for July-December, 2022 as against Tk. 0.34 for July-December, 2021. NOCFPS was Tk. 7.69 for July-December, 2022 as against Tk. 4.21 for July-December, 2021. NAV per share was Tk. 21.56 as on December 31, 2022 and Tk. 21.96 as on June 30, 2022. Reasons for Deviation in NOCFPS: NOCFPS increased due to decrease of payments for cost and expenses.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 25, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
- BSEC rejected issuance of 20% Stock Dividend
Refer to their earlier news disseminated by DSE on 23.11.2022 regarding Dividend Declaration (Additional Information), the company has further informed that the decision regarding raising of paid-up capital through issuance of 20% stock dividend for the year ended June 30, 2022 has not been approved by Bangladesh Securities and Exchange Commission.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.